Where most study results support and recommend a two-antibody testing algorithm46–50, one recent study of a cohort of CRC challenged its use as it observed cases with complete loss of MSH2 expression in combination with heterogeneous staining of MSH651. The gene discussed is MSH2; the disease is colorectal carcinoma.